← Nippon India Mutual Fund

Nippon India Nifty Pharma ETF

Index/ETF Data as of Sep 2026 Comparing Aug 2026 → Sep 2026
Share: WhatsApp X
Stocks Held
20
Sep 2026
Equity Holdings
₹1,735.81 Cr
Equity only, excl. debt & cash
Top 5 Weight
54.6%
High concentration
Top 10 Weight
78.2%
High concentration
Changes
18
0 new · 0 exits
Top Sector
Pharmaceuticals & Biotechnology
99.9% of portfolio
Launch Date
21 Jun 2021
5 years old
📋 What Happened This Month Among existing holdings, Dr. Reddy's Laboratories Limited saw the biggest increase — now at 7.62% of the portfolio. Sun Pharmaceutical Industries Limited was trimmed the most, now at 19.50%. Sun Pharmaceutical Industries Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 99.9%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Jul 2026 → Aug 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 99.8% 100.0% ▲ +0.2%
Aug 2026 → Sep 2026
Sector Prev Curr ▼ Delta
Pharmaceuticals & Biotechnology 100.0% 99.9% ● 0.0%
↑
Biggest Add
Dr. Reddy's Laboratories Limited
+0.67% · now 7.62%
↓
Biggest Trim
Sun Pharmaceutical Industries Limited
-1.25% · now 19.50%

What Changed in the Portfolio This Month?

Comparing Aug 2026 → Sep 2026

Aug 2026 → Sep 2026
↑ 11 Increased ↓ 7 Decreased
#StockSectorAug 2026Sep 2026Change
1
Dr. Reddy's Laboratories Limited
₹132.40 Cr
Pharmaceuticals & Biotechnology 6.95% 7.62% +0.67%
2
Laurus Labs Limited
₹135.78 Cr
Pharmaceuticals & Biotechnology 7.36% 7.82% +0.46%
3
Wockhardt Limited
₹30.78 Cr
Pharmaceuticals & Biotechnology 1.54% 1.77% +0.23%
4
Mankind Pharma Limited
₹49.96 Cr
Pharmaceuticals & Biotechnology 2.70% 2.88% +0.18%
5
Ajanta Pharma Limited
₹29.06 Cr
Pharmaceuticals & Biotechnology 1.50% 1.67% +0.17%
6
Sai Life Sciences Limited
₹37.13 Cr
Pharmaceuticals & Biotechnology 1.99% 2.14% +0.15%
7
Abbott India Limited
₹24.89 Cr
Pharmaceuticals & Biotechnology 1.33% 1.43% +0.10%
8
Divi's Laboratories Limited
₹207.93 Cr
Pharmaceuticals & Biotechnology 11.88% 11.97% +0.09%
9
Alkem Laboratories Limited
₹54.82 Cr
Pharmaceuticals & Biotechnology 3.08% 3.16% +0.08%
10
Gland Pharma Limited
₹40.69 Cr
Pharmaceuticals & Biotechnology 2.27% 2.34% +0.07%
#StockSectorAug 2026Sep 2026Change
1
Sun Pharmaceutical Industries Limited
₹338.68 Cr
Pharmaceuticals & Biotechnology 20.75% 19.50% -1.25%
2
Biocon Limited
₹45.44 Cr
Pharmaceuticals & Biotechnology 2.90% 2.62% -0.28%
3
Lupin Limited
₹86.83 Cr
Pharmaceuticals & Biotechnology 5.25% 5.00% -0.25%
4
Torrent Pharmaceuticals Limited
₹124.37 Cr
Pharmaceuticals & Biotechnology 7.34% 7.16% -0.18%
5
Cipla Limited
₹133.37 Cr
Pharmaceuticals & Biotechnology 7.83% 7.68% -0.15%
6
Glenmark Pharmaceuticals Limited
₹61.89 Cr
Pharmaceuticals & Biotechnology 3.69% 3.56% -0.13%
7
Piramal Pharma Limited
₹22.59 Cr
Pharmaceuticals & Biotechnology 1.32% 1.30% -0.02%

What Stocks Does This Fund Hold?

20 stocks — Sep 2026

# Stock Sector Cap Weight & Value
1
₹338.68 Cr
Pharmaceuticals & Biotechnology
19.50%
2
₹207.93 Cr
Pharmaceuticals & Biotechnology
11.97%
3
₹135.78 Cr
Pharmaceuticals & Biotechnology
7.82%
4
₹133.37 Cr
Pharmaceuticals & Biotechnology
7.68%
5
₹132.40 Cr
Pharmaceuticals & Biotechnology
7.62%
6
₹124.37 Cr
Pharmaceuticals & Biotechnology
7.16%
7
₹86.83 Cr
Pharmaceuticals & Biotechnology
5.00%
8
₹81.36 Cr
Pharmaceuticals & Biotechnology
4.69%
9
₹61.89 Cr
Pharmaceuticals & Biotechnology
3.56%
10
₹54.82 Cr
Pharmaceuticals & Biotechnology
3.16%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
→
🏦 Nippon India Mutual Fund — Portfolio & Holdings
See all funds managed by Nippon India Mutual Fund — conviction stocks, monthly entries & exits
→

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.